Nektar Therapeutics (NKTR) Leases (2016 - 2025)
Historic Leases for Nektar Therapeutics (NKTR) over the last 12 years, with Q3 2025 value amounting to $7.2 million.
- Nektar Therapeutics' Leases fell 1875.14% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year decrease of 1875.14%. This contributed to the annual value of $8.4 million for FY2024, which is 5327.93% down from last year.
- Nektar Therapeutics' Leases amounted to $7.2 million in Q3 2025, which was down 1875.14% from $7.6 million recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Leases registered a high of $125.0 million during Q1 2021, and its lowest value of $7.2 million during Q3 2025.
- Its 5-year average for Leases is $50.6 million, with a median of $29.0 million in 2023.
- Its Leases has fluctuated over the past 5 years, first plummeted by 666.91% in 2021, then plummeted by 7155.06% in 2023.
- Nektar Therapeutics' Leases (Quarter) stood at $117.0 million in 2021, then tumbled by 54.34% to $53.4 million in 2022, then tumbled by 66.3% to $18.0 million in 2023, then plummeted by 53.28% to $8.4 million in 2024, then dropped by 14.76% to $7.2 million in 2025.
- Its last three reported values are $7.2 million in Q3 2025, $7.6 million for Q2 2025, and $8.0 million during Q1 2025.